Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension

Table 1 Results of 5-years follow-up n (%)

Items	Patients
Refractory ascites or hydrothorax	15 (7.2)
EGVB	77 (36.8)
Hepatic encephalopathy	82 (39.2)
Distributary channel restenosis (yr)
1	36 (17.2)
2	62 (29.7)
3	77 (36.8)
4	95 (45.5)
5	122 (58.4)
Interventional treatments
RFA	113 (54.1)
Once	34 (30.1)
Twice	42 (37.2)
Thrice or more	37 (32.7)
TACE/TAE	185 (88.5)
Once	31 (16.8)
Twice	42 (22.7)
Thrice or more	112 (60.5)
Fistula embolization	22 (10.5)
Once	6 (27.3)
Twice	14 (63.6)
Thrice or more	2 (9.1)
Splenic artery embolization	14 (6.7)
Once	7 (50.0)
Twice	6 (42.9)
Thrice or more	1 (7.1)
Interventional re-treatments	102 (48.8)
Twice	62 (60.8)
Thrice or more	40 (39.2)
Balloon angioplasty	9 (8.8)
Stent angioplasty	93 (91.2)

EGVB: Esophageal gastric-fundus variceal bleeding; TACE: Transarterial chemoembolization; TAE: Transarterial embolization; RFA: Radiofrequency ablation.